Search - tctmd.com

Displaying 701 - 720 of 740

Sort: Relevancy | Date

Presentation TCT 2016

TVA Medical Approach

Presenter: Mitchell W. Krucoff, Katherine Kumar

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Occlutech LAA Occluder (and Future studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Horst Sievert

October 30, 2016

Presentation TCT 2016

Synthesis of ACP/Amulet Studies in Anticoagulated Indicated and Contra-indicated Patients: Certainties, Data Gaps, and Future Studies

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Apostolos Tzikas

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Sara Takahashi

October 30, 2016

Presentation TCT 2016

Real-world Watchman Outcomes: Insights From the EWOLUTION European Registry

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Martin W. Bergmann

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Rachel Neubrander

October 30, 2016

Presentation TCT 2016

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, David R. Holmes Jr.

October 30, 2016

Presentation TCT 2016

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Presenter: Mitchell W. Krucoff, Shigeru Saito, Kenneth Stein, MD

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Presenter: Mitchell W. Krucoff, Shigeru Saito, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Matthew J. Price

October 30, 2016

Presentation TCT 2016

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Marc Gillinov

October 30, 2016

Presentation TCT 2016

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Vivek Y. Reddy

October 30, 2016

Presentation TCT 2016

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michelle O'Donoghue

October 30, 2016

Presentation TCT 2016

Impact of LAA Exclusion on Neurohormonal Modulation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation: Scope of the Problem

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Michael D. Ezekowitz

October 30, 2016

Advertisement

TVA Medical Approach

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Early and Late Results With the Occlutech LAA Occluder (and Future studies)

Synthesis of ACP/Amulet Studies in Anticoagulated Indicated and Contra-indicated Patients: Certainties, Data Gaps, and Future Studies

Appropriate Use Criteria of LAA Closure Devices: PMDAs View

Real-world Watchman Outcomes: Insights From the EWOLUTION European Registry

Appropriate Use Criteria of LAA Closure Devices: FDAs View

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Appropriate Use Criteria of LAA Closure Devices: US Industry View

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Differences Between US and Japan in OAT Discontinuation and Risk of Major Bleeds, and Who are the Best LAA Closure Device Candidates in Both Countries

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Risk Scores for Stroke Risk and Bleeding in Atrial Fibrillation: Accuracy and Utility in Trials and the Real World

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

What are Valid Absolute and Relative Contraindications to Warfarin and NOACs?

Warfarin and NOACS for Atrial Fibrillation: Efficacy, Complications, and Compliance

Impact of LAA Exclusion on Neurohormonal Modulation

Role of LAA in Atrial Arrhythmias: Origin and Maintenance

Atrial Fibrillation: Scope of the Problem

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content